TB and HIV/AIDS (coming soon)
The Lilly MDR-TB Partnership was created in 2003 to combat multidrug-resistant tuberculosis (MDR-TB). The International Hospital Federation has been a member of the project since 2004.
The IHF bilateral partnership was created in 2004 upon recognition of the need, firstly, to address TB management/treatment from the perspective of the hospital/healthcare setting.
Secondly, and even more importantly, upon acknowledgment that 'ignorance' and exclusion of IHF membership group, may have led and can lead to adoption and implementation of contra-productive decisions and actions in the fight against MDR-TB.
Despite recent progress, tuberculosis (TB) remains an important global public health problem. One-third of the world's population is currently infected with the tubercle bacillus that causes TB; and, according to the World Health Organization (WHO), there were 9.4 million new cases and 1.7 million deaths from TB in 2009.
Although TB is curable, inadequate TB control is one of the factors that has led to an increase in multidrug-resistant tuberculosis (MDR-TB), a particularly dangerous form of the disease, which is potentially incurable in many settings. MDR-TB is defined as disease caused by TB bacilli resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs. Rates of MDR-TB are high in some countries and, coupled with the devastating effects of TB/HIV co-infection, threaten to undermine TB control efforts worldwide.
The Union has been a leader in tuberculosis prevention, control and treatment since it was founded in 1920 as the International Union Against Tuberculosis. It is mostly widely known for the research that led to the directly observed treatment, short course (DOTS) strategy, endorsed by the WHO and used to treat more than 37 million TB patients around the world.
The ICN TB Project’s ‘Leading Lights’ initiative was launched on 17 June 2014 at the WHO headquarters.
This initiative aims to showcase the work of exceptional nurses and other health care workers who have made a valuable contribution to TB prevention, care and management in their local facility and/or community.
The launch, which was attended by members of the WHO Strategic and Technical Advisory Group for Tuberculosis, included presentations about the Leading Lights Initiative and the work of the ICN TB Project from Evan Lee, Vice President, Global Health Programs and Access, Eli Lilly and Company; David Benton, Chief Executive Officer of ICN; and Gini Williams, TB Project Director.
ICN has been part of the Lilly MDR/TB Partnership since 2005 and since then has reached more than 90,000 nurses and allied health workers in China, Colombia, Egypt, Ethiopia, India, Indonesia, Kenya, Lesotho, Malawi, Mozambique, Philippines, Russia, Senegal, South Africa, Swaziland, Togo, Uganda, and Zambia. A United Way Worldwide grant made possible by the Lilly Foundation supports the project, which uses a transformational training methodology, designed specifically to encourage practice development. Experienced nurses working mainly in TB and HIV are trained to cascade information to nursing colleagues and other health workers to improve patient care delivery.
The “Leading Lights” award recognises outstanding contribution to the care of people affected by TB.
Eligibility: the nominee must be nurse or health care worker who
Who can nominate someone as a ‘Leading Light’?
The New Jersey Medical School Global Tuberculosis Institute at Rutgers, The State University of New Jersey is a force in the effort to conquer and cure tuberculosis worldwide. The Institute plays a leading role in the international arena, providing expertise in program development, education and training and research to ministers of health, national TB programs and healthcare providers around the globe.
The Institute's work has no borders. Battling TB on the front lines, it has a proven track record in building the political will and international cooperation needed to relegate this disease to the history books, where it belongs.